Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non‐interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials

BACKGROUND: Prognosis of patients with multiple myeloma (MM) who have relapsed on or become refractory to immunomodulators and bortezomib is poor, and treatment options are limited. While pomalidomide plus low‐dose dexamethasone (POM/DEX) has demonstrated efficacy in clinical trials, real‐world evid...

Descripción completa

Detalles Bibliográficos
Autores principales: Dechow, Tobias, Aldaoud, Ali, Behlendorf, Timo, Knauf, Wolfgang, Eschenburg, Henning, Groschek, Matthias, Hansen, Richard, Söling, Ulrike, Grebhardt, Sina, Siebenbach, Hans Ulrich, Vannier, Corinne, Potthoff, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298817/
https://www.ncbi.nlm.nih.gov/pubmed/34714555
http://dx.doi.org/10.1111/ejh.13719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298817/
https://www.ncbi.nlm.nih.gov/pubmed/34714555
http://dx.doi.org/10.1111/ejh.13719

Ejemplares similares